Beta Bionics (BBNX) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$17.63
+1.1% on the day
-20.7% over 12 months
52-week range $8.86 – $31.99
Share price and insider trades
BBNX closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$5.4M
Insiders buying0
Insiders selling8
Beta Bionics insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 8 sold $5.4M of BBNX stock on the open market.
Get emailed when insiders cluster-buy stocks like BBNX
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
BBNX insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $7K | 1 |
| Q3 2026 | — | 0 | $3.0M | 12 |
| Q2 2026 | — | 0 | $937K | 16 |
| Q1 2026 | — | 0 | $987K | 10 |
| Q4 2025 | — | 0 | $866K | 18 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day0.8×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Beta Bionics, Inc. insiders reported open-market purchases totaling $0, while 8 insiders reported sales totaling $5.4M. 38 of 57 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 5SEC | Mark HopmanChief Commercial Officer | Sell Plan | 37056,109 held (−1%) | $18.96 | $7K | -7.0% | — |
| Sep 23SEC | Christy JonesDirector | Sell Plan | 6,43019,564 held (−25%) | $23.00 | $148K | -23.3% | — |
| Sep 18SEC | Mark HopmanChief Commercial Officer | Sell Plan | 35,99488,033 held (−29%) | $18.46 | $664K | -4.5% | — |
| Sep 17SEC | Mark HopmanChief Commercial Officer | Sell Plan | 30,77956,479 held (−35%) | $20.13 | $620K | -12.4% | — |
| Sep 17SEC | Mike MensingerChief Product Officer | Sell Plan | 2,650177,390 held (−1%) | $22.00 | $58K | -19.9% | — |
| Sep 15SEC | Mark HopmanChief Commercial Officer | Sell Plan | 77586,382 held (−1%) | $15.52 | $12K | +13.6% | — |
| Sep 10SEC | Mark HopmanChief Commercial Officer | Sell Plan | 36,87087,157 held (−30%) | $18.46 | $681K | -4.5% | — |
| Sep 4SEC | Sean SaintCEO, President | Sell Plan | 5,641398,429 held (−1%) | $20.08 | $113K | -12.2% | — |
| Sep 3SEC | Sean SaintCEO, President | Sell | 16,867404,070 held (−4%) | $19.11 | $322K | -7.7% | — |
| Sep 3SEC | Stephen FeiderCFO | Sell | 6,675159,378 held (−4%) | $19.11 | $128K | -7.7% | — |
| Sep 3SEC | Mark HopmanChief Commercial Officer | Sell | 5,327124,027 held (−4%) | $19.11 | $102K | -7.7% | — |
| Sep 3SEC | Mike MensingerChief Product Officer | Sell | 4,375180,040 held (−2%) | $19.11 | $84K | -7.7% | — |
| Sep 3SEC | Steven Jon RussellChief Medical Officer | Sell | 4,221169,628 held (−2%) | $19.11 | $81K | -7.7% | — |
| Jul 2SEC | Stephen FeiderCFO | Sell Plan | 5,104166,053 held (−3%) | $17.05 | $87K | +3.4% | — |
| Jul 2SEC | Stephen FeiderCFO | Sell Plan | 4,896166,053 held (−3%) | $17.03 | $83K | +3.5% | — |
| Jun 30SEC | Stephen FeiderCFO | Sell Plan | 5,104165,931 held (−3%) | $17.05 | $87K | +3.4% | — |
| Jun 30SEC | Stephen FeiderCFO | Sell Plan | 4,896165,931 held (−3%) | $17.03 | $83K | +3.5% | — |
| Jun 25SEC | Christy JonesDirector | Sell Plan | 1,40625,994 held (−5%) | $15.00 | $21K | +17.5% | — |
| Jun 25SEC | Mark HopmanChief Commercial Officer | Sell Plan | 1,258129,354 held (−1%) | $15.01 | $19K | +17.5% | — |
| Jun 5SEC | Christy JonesDirector | Sell Plan | 2,81127,400 held (−9%) | $14.00 | $39K | +25.9% | — |
| Jun 5SEC | Mark HopmanChief Commercial Officer | Sell Plan | 275130,612 held (−0%) | $12.31 | $3K | +43.2% | — |
| Jun 3SEC | Sean SaintCEO, President | Sell | 16,872420,937 held (−4%) | $12.61 | $213K | +39.8% | — |
| Jun 3SEC | Stephen FeiderCFO | Sell | 6,676166,053 held (−4%) | $12.61 | $84K | +39.8% | — |
| Jun 3SEC | Mark HopmanChief Commercial Officer | Sell | 5,329130,887 held (−4%) | $12.61 | $67K | +39.8% | — |
| Jun 3SEC | Mike MensingerChief Product Officer | Sell | 4,378184,415 held (−2%) | $12.61 | $55K | +39.8% | — |
| Jun 3SEC | Steven Jon RussellChief Medical Officer | Sell | 4,222173,849 held (−2%) | $12.61 | $53K | +39.8% | — |
| May 26SEC | Christy JonesDirector | Sell Plan | 1,99813,246 held (−13%) | $9.95 | $20K | +77.2% | — |
| May 26SEC | Adam LezackDirector | Sell Plan | 99827,399 held (−4%) | $11.21 | $11K | +57.3% | — |
| May 26SEC | Adam LezackDirector | Sell Plan | 1,00011,432 held (−8%) | $9.95 | $10K | +77.2% | — |
| Mar 16SEC | Mark HopmanChief Commercial Officer | Sell Plan | 2,061136,216 held (−1%) | $30.66 | $63K | -42.5% | — |
| Mar 16SEC | Steven Jon RussellChief Medical Officer | Sell | 1,025178,071 held (−1%) | $29.34 | $30K | -39.9% | — |
| Mar 16SEC | Mark HopmanChief Commercial Officer | Sell Plan | 856138,277 held (−1%) | $29.34 | $25K | -39.9% | — |
| Mar 5SEC | Mark HopmanChief Commercial Officer | Sell Plan | 353139,133 held (−0%) | $11.57 | $4K | +52.4% | — |
| Mar 3SEC | Sean SaintCEO, President | Sell | 3,384437,809 held (−1%) | $12.36 | $42K | +42.6% | — |
| Mar 3SEC | Stephen FeiderCFO | Sell | 1,428172,729 held (−1%) | $12.36 | $18K | +42.6% | — |
| Mar 3SEC | Mike MensingerChief Product Officer | Sell | 1,064188,793 held (−1%) | $12.36 | $13K | +42.6% | — |
| Mar 3SEC | Steven Jon RussellChief Medical Officer | Sell | 1,026179,096 held (−1%) | $12.36 | $13K | +42.6% | — |
| Mar 3SEC | Mark HopmanChief Commercial Officer | Sell | 834139,486 held (−1%) | $12.36 | $10K | +42.6% | — |
| Jan 7SEC | Mike MensingerChief Product Officer | Sell Plan | 2,20080,752 held (−3%) | $30.10 | $66K | -41.4% | — |
| Jan 5SEC | Stephen FeiderCFO | Sell Plan | 20,00042,614 held (−32%) | $29.53 | $591K | -40.3% | — |
| Jan 5SEC | Mike MensingerChief Product Officer | Sell Plan | 7,20083,552 held (−8%) | $29.56 | $213K | -40.4% | — |
| Jan 5SEC | Mike MensingerChief Product Officer | Sell Plan | 60082,952 held (−1%) | $30.20 | $18K | -41.6% | — |
| Dec 4SEC | Sean SaintCEO, President | Sell | 3,27897,924 held (−3%) | $29.34 | $96K | -39.9% | — |
| Dec 4SEC | Stephen FeiderCFO | Sell | 1,42742,614 held (−3%) | $29.34 | $42K | -39.9% | — |
| Dec 4SEC | Mike MensingerChief Product Officer | Sell | 1,06390,752 held (−1%) | $29.34 | $31K | -39.9% | — |
| Dec 2SEC | Adam LezackDirector | Sell Plan | 9068,935 held (−9%) | $29.35 | $27K | -39.9% | — |
| Dec 2SEC | Maria PalasisDirector | Sell Plan | 9068,935 held (−9%) | $29.33 | $27K | -39.9% | — |
| Dec 2SEC | Maria PalasisDirector | Sell Plan | 5008,435 held (−6%) | $29.96 | $15K | -41.2% | — |
| Dec 2SEC | Adam LezackDirector | Sell Plan | 5008,435 held (−6%) | $29.91 | $15K | -41.1% | — |
| Nov 5SEC | Adam LezackDirector | Sell Plan | 1,3689,879 held (−12%) | $26.85 | $37K | -34.3% | — |
| Nov 5SEC | Maria PalasisDirector | Sell Plan | 1,2879,960 held (−11%) | $26.86 | $35K | -34.4% | — |
| Nov 5SEC | Maria PalasisDirector | Sell Plan | 1199,841 held (−1%) | $27.45 | $3K | -35.8% | — |
| Nov 5SEC | Adam LezackDirector | Sell Plan | 389,841 held (−0%) | $27.70 | $1K | -36.4% | — |
| Oct 7SEC | Stephen FeiderCFO | Sell Plan | 3,82845,195 held (−8%) | $21.52 | $82K | -18.1% | — |
| Oct 7SEC | Stephen FeiderCFO | Sell Plan | 1,15444,041 held (−3%) | $22.28 | $26K | -20.9% | — |
| Oct 3SEC | Stephen FeiderCFO | Sell Plan | 14,91844,141 held (−25%) | $20.76 | $310K | -15.1% | — |
| Oct 3SEC | Stephen FeiderCFO | Sell Plan | 10044,041 held (−0%) | $21.08 | $2K | -16.4% | — |
Insiders at Beta Bionics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Mark HopmanChief Commercial Officer | — | $2.3M | Oct 5, 2026 | — |
| Stephen FeiderCFO | — | $1.6M | Sep 3, 2026 | — |
| Sean SaintCEO, President | — | $786K | Sep 4, 2026 | — |
| Mike MensingerChief Product Officer | — | $539K | Sep 17, 2026 | — |
| Christy JonesDirector | — | $228K | Sep 23, 2026 | — |
| Steven Jon RussellChief Medical Officer | — | $177K | Sep 3, 2026 | — |
| Adam LezackDirector | — | $100K | May 26, 2026 | — |
| Maria PalasisDirector | — | $79K | Dec 2, 2025 | — |
BBNX stock: common questions
Are Beta Bionics, Inc. insiders buying BBNX stock?
In the past 12 months, 0 insiders reported open-market purchases of BBNX worth $0.
Are Beta Bionics, Inc. insiders selling BBNX stock?
8 insiders reported sales worth $5.4M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is BBNX's 52-week range?
Over the past year BBNX has traded between $8.86 and $31.99. It last closed at $17.63 on Oct 9, 2026.